Prnewswire·2026-02-05 13:30Core Viewpoint - Atossa Therapeutics has reaffirmed its strong market position in the Duchenne Muscular Dystrophy (DMD) program following the reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) Program, which allows for potential future PRV eligibility upon FDA approval of (Z)-endoxifen for DMD treatment [1][3] Group 1: Rare Pediatric Disease Designation - The Rare Pediatric Disease (RPD) designation is granted to drug candidates for serious or life-threatening diseases affecting individuals from birth to 18 years old, allowing for eligibility for a PRV upon FDA approval [2][4] - PRVs can be used for priority review of future applications or sold to other sponsors, with recent PRV sales ranging from $150 million to $200 million [2] Group 2: Company Statements and Insights - The renewal of the PRV program signals congressional recognition of the complexities and financial burdens in drug development, validating the potential of (Z)-endoxifen for DMD treatment [3] - Atossa's leadership emphasizes the urgent need for better treatment options for DMD beyond current therapies, highlighting (Z)-endoxifen's broader treatment approach [3] Group 3: Product and Market Potential - (Z)-endoxifen is a Selective Estrogen Receptor Modulator/Degrader (SERM/D) with a favorable safety profile and distinct pharmacology, currently not approved for any indication [6] - The company is advancing (Z)-endoxifen's development in both oncology and rare diseases, supported by a growing global intellectual property portfolio [7][8]